News - Page 17 of 17 - Heartland Cancer Research

Journal of American Medical Association (JAMA) Publication
June 22, 2021

Dr. Pankaj Kumar – Published in Journal of American Medical Association (JAMA) – the most widely circulated general medical journal of peer-reviewed articles in the world. Congratulations to Dr. Pankaj Kumar of Illinois CancerCare and the Heartland NCI Community Oncology Research Program on this Achievement! Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy […]

Cancer Clinical Trials in Your Community – NCI Community Oncology Research Program (NCORP)
September 4, 2019

ACCC Awards James L. Wade III, M.D. Community Clinical Scientist Award
October 8, 2018

The David King Community Clinical Scientist Award recognizes active community clinical research leaders who have demonstrated leadership in the development, participation, and evaluation of clinical studies and/or are active in the development of new screening, risk assessment, treatment, or supportive care programs for cancer patients. James L. Wade III, MD, FACP, FASCO Medical Oncologist, Founder, […]

I Live To Conquer Cancer – Dr. Alan Lyss
September 11, 2018

Our very own Alan P. Lyss, MD, an oncologist at the Missouri Baptist Medical Center, Heartland Cancer Research NCORP, highlights the importance of bringing cutting-edge cancer research to rural communities.

ASCO Highlights 2018
August 27, 2018

Heartland’s Contributions to Research Presented at ASCO 2018  At the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), National Cancer Institute (NCI) Director Norman Sharpless, MD, announced $10 million in new funding for the National Clinical Trials Network (NCTN). The NCTN consists of five U.S. research bases that develop and conduct cancer clinical […]

Publicly Funded Cancer Trials Save More Than 3 Million Years of Life
August 23, 2017

People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting.

Heartland NCORP involved in Groundbreaking Research
July 18, 2017

At the ASCO 2017 Meeting, Heartland investigators were proud to hear presentations and discussions about studies in which our patients participated and in which our doctors and staff played a significant role in generating new discoveries.

NCI-MATCH Cancer Trial reaches Goal 2 years Early
June 7, 2017

This precision medicine trial continues with a new study entry process that casts a wider net for patients through routine genomic testing. Within Heartland, we had 164 continue toward the 6,000 patient goal that was reached two years early.

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
January 3, 2017

Bone involvement in metastatic cancer is a common clini-cal problem. The US Food and Drug Administration ap-proved zoledronic acid, a third-generation aminobis-phosphonate, for the treatment of patients with multiple myeloma and bone metastases from solid tumors.

Obama signs 21st Century Cures Act at the White House
December 13, 2016

USA Today In an emotional bill signing ceremony — likely the last one of this presidency — Obama signed the 21st Century Cures Act in a White House auditorium. The signing brought full circle Obama’s State of the Union challenge to Congress to “surprise the cynics” by tackling some of the biggest health priorities facing the country. […]